SCHEDULE: 180 Life Sciences CEO Jordan's Ownership Shifts

Blair Jordan's beneficial ownership in 180 Life Sciences Corp. has fallen below 5% following new option grants and accelerated vesting of restricted stock.

Summary

• This Amendment No. 4 to Schedule 13D was filed by Blair Jordan to disclose the grant of certain options to an entity he controls, the exercisability of previously granted options, and his beneficial ownership falling below 5% of the Issuer's outstanding common stock.
• Blair Jordan's aggregate beneficial ownership is 2,298,742 shares, representing 1.5% of the 154,032,084 shares of common stock outstanding as of August 5, 2025.
• He holds sole voting power over 160,000 shares and shared voting power over 2,138,742 shares, with sole dispositive power over 160,000 shares and no shared dispositive power.
• Mr. Jordan's beneficial ownership includes shares subject to irrevocable voting proxies from Dr. James Woody (43,166 shares until February 5, 2026), Dr. Marlene Krauss (200,000 shares until August 21, 2025), and Elray Resources, Inc. (1,318,000 shares until April 28, 2026).
• 160,000 restricted common shares granted to Mr. Jordan in February 2025, originally vesting in 2026, had their vesting accelerated in full on June 17, 2025.
• Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan) received a grant of 410,000 stock options on June 17, 2025, with an exercise price of $0.9290 per share; their vesting was accelerated on July 12, 2025, and they became exercisable on July 24, 2025, upon stockholder approval of the 2025 Option Incentive Plan.
• Jordan Consulting also received 167,576 restricted common shares on June 17, 2025, which had their vesting accelerated in full on July 12, 2025.
• On July 29, 2025, 3,908,986 stock options were granted to Blair Jordan (in the name of Jordan Consulting) under the 2025 Supplemental Option Plan, with an exercise price of $2.92 per share.
• These 3,908,986 options are not exercisable until the closing of a Securities Purchase Agreement (which occurred on August 4, 2025) and require stockholder approval of the 2025 Supplemental Plan by July 29, 2026, or they will be cancelled.
• Blair Jordan ceased to be the beneficial owner of more than five percent of the Issuer's common stock on August 4, 2025.

Sentiment

Score: 6

Explanation: The filing indicates ongoing executive compensation and strategic voting agreements, which are generally positive for management alignment. However, the CEO's beneficial ownership falling below 5% might be viewed with mixed sentiment, though it's explained by share count increases and the nature of proxies. The large new option grant is positive, but its contingency on future stockholder approval introduces a minor uncertainty.

Positives

• The acceleration of vesting for 160,000 restricted shares and 410,000 options, along with 167,576 restricted shares, indicates a commitment to executive compensation and potentially reflects confidence in management.
• The grant of 3,908,986 new stock options to the CEO (via Jordan Consulting) aligns his long-term incentives with the company's performance, contingent on future stockholder approval.
• Stockholder approval of the 2025 Option Incentive Plan on July 24, 2025, demonstrates shareholder support for the company's equity compensation framework.

Negatives

• Blair Jordan's beneficial ownership percentage falling below 5% could be perceived negatively by some investors, although it is explained by the increase in outstanding shares and the nature of the voting proxies.
• The exercisability and validity of the substantial 3,908,986 stock options granted on July 29, 2025, are contingent on future stockholder approval of the 2025 Supplemental Option Plan by July 29, 2026; failure to obtain this approval will result in their cancellation.

Risks

• The 3,908,986 stock options granted under the 2025 Supplemental Option Plan are subject to stockholder approval by July 29, 2026; if this approval is not obtained, the options will be unwound and cancelled, potentially impacting executive incentives.

Future Outlook

The Reporting Person may purchase additional securities of the Issuer or dispose of some or all of the securities he currently owns from time to time in open market transactions, private transactions or otherwise. He may also acquire additional shares of common stock under various employee benefit and compensation arrangements in the future. The 3,908,986 stock options granted on July 29, 2025, are contingent on stockholder approval of the 2025 Supplemental Option Plan by July 29, 2026.

Management Comments

• "The Reporting Person acquired the securities for investment purposes."
• "The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into a plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by him, in any manner permitted by law."

Industry Context

NA

Corporate Governance

Related Party Transactions

• Executive Consulting Agreement entered into on February 20, 2025, between the Issuer, Blair Jordan, and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan).
• Grant of 160,000 restricted common shares to Mr. Jordan in February 2025.
• Grant of 410,000 stock options and 167,576 restricted common shares to Blair Jordan Strategy and Finance Consulting Inc. on June 17, 2025.
• Grant of 3,908,986 stock options to Blair Jordan (in the name of Jordan Consulting) on July 29, 2025.

Stakeholder Impact

• Shareholders: Potential for future dilution from the exercise of newly granted options. The significant equity compensation for the CEO aims to align his interests with long-term shareholder value. Voting agreements consolidate voting power for Board recommendations.
• Management/Employees: The CEO receives substantial equity compensation, incentivizing his continued service and performance, which could benefit the company's strategic direction.

Next Steps

• Stockholder approval of the 2025 Supplemental Option Plan is required prior to July 29, 2026, for the 3,908,986 options granted on July 29, 2025, to remain valid and exercisable.

Key Dates

Recommendation

The filing primarily details changes in executive compensation and beneficial ownership, which are largely expected for a CEO. While the significant new option grants align management incentives, the decrease in the CEO's overall beneficial ownership percentage below 5% (due to increased share count and proxy nature) might be viewed with mixed sentiment. The contingency of the largest option grant on future stockholder approval introduces a minor uncertainty. There are no immediate strong catalysts or red flags for a 'buy' or 'sell' recommendation based solely on this ownership update.

Keywords

180 Life Sciences, Blair Jordan, Schedule 13D, Beneficial Ownership, Stock Options, Restricted Stock, Executive Compensation, Corporate Governance, Voting Agreement, SEC Filing